BR112016013516A2 - - Google Patents

Info

Publication number
BR112016013516A2
BR112016013516A2 BR112016013516A BR112016013516A BR112016013516A2 BR 112016013516 A2 BR112016013516 A2 BR 112016013516A2 BR 112016013516 A BR112016013516 A BR 112016013516A BR 112016013516 A BR112016013516 A BR 112016013516A BR 112016013516 A2 BR112016013516 A2 BR 112016013516A2
Authority
BR
Brazil
Application number
BR112016013516A
Other languages
Portuguese (pt)
Other versions
BR112016013516A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112016013516A2 publication Critical patent/BR112016013516A2/pt
Publication of BR112016013516A8 publication Critical patent/BR112016013516A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112016013516A 2013-12-12 2014-12-12 complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula BR112016013516A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915429P 2013-12-12 2013-12-12
PCT/US2014/070176 WO2015089487A1 (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Publications (2)

Publication Number Publication Date
BR112016013516A2 true BR112016013516A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-08-08
BR112016013516A8 BR112016013516A8 (pt) 2020-05-19

Family

ID=52273587

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013516A BR112016013516A8 (pt) 2013-12-12 2014-12-12 complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula

Country Status (11)

Country Link
US (5) US9856496B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP3079723B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP6912887B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102532559B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN106456793B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2014361806B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112016013516A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2933561A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2808866T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG11201604697TA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2015089487A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051089C (en) * 2012-05-02 2022-04-12 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
CN104583956B (zh) 2012-06-15 2019-01-04 英特尔公司 用于实现加载存储重新排序和优化的指令定义
CN104823168B (zh) 2012-06-15 2018-11-09 英特尔公司 用于实现从由加载存储重新排序和优化导致的推测性转发遗漏预测/错误中恢复的方法和系统
KR101996462B1 (ko) 2012-06-15 2019-07-04 인텔 코포레이션 명확화 없는 비순차 load store 큐
CN104583943B (zh) 2012-06-15 2018-06-08 英特尔公司 拥有具有分布式结构的动态分派窗口的虚拟加载存储队列
CN104823154B (zh) 2012-06-15 2017-12-29 英特尔公司 包括虚拟加载存储队列的处理器和系统
WO2013188306A1 (en) 2012-06-15 2013-12-19 Soft Machines, Inc. Reordered speculative instruction sequences with a disambiguation-free out of order load store queue
EP3079723B1 (en) 2013-12-12 2020-05-27 Life Technologies Corporation Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US20170016043A1 (en) 2015-07-13 2017-01-19 Life Technologies Corporation System and method for improved transient protein expression in cho cells
CN108779074A (zh) * 2016-03-01 2018-11-09 分子传递有限公司 植物病毒移动蛋白和其使用方法
EP3500585A4 (en) 2016-08-17 2020-04-01 Factor Bioscience Inc. NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION
US11414675B2 (en) * 2016-09-30 2022-08-16 Life Technologies Corporation Serum-free suspension system for lentiviral production
US11782050B2 (en) 2017-09-19 2023-10-10 Cannametrix, Llc Cell-based assay for quantifying the potency and efficacy of cannabinoids and/or terpenoids, and methods of use thereof
WO2019178479A1 (en) * 2018-03-16 2019-09-19 Sarepta Therapeutics, Inc. Chimeric peptides for antisense delivery
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
US11608491B2 (en) 2019-02-22 2023-03-21 Life Technologies Corporation Suspension system for adeno associated virus production
EP4005583A4 (en) * 2019-04-01 2023-04-26 Industry - University Cooperation Foundation Hanyang University CP2C TARGETING PEPTIDE ANTICANCER AGENT
KR102261371B1 (ko) * 2019-04-01 2021-06-08 한양대학교 산학협력단 CP2c 표적 펩티드 기반 항암제
EP4010028A1 (en) * 2019-08-05 2022-06-15 PolyPlus Transfection Compositions for transfecting a nucleic acid molecule into a cell comprising triazole compounds grafted to a cationic polymer, and their applications
KR102515464B1 (ko) * 2020-04-29 2023-03-28 연세대학교 원주산학협력단 핵산 또는 유전자 형질감염 효율을 개선하는 세포독성 완화 막 투과 펩타이드 및 이의 용도
CA3207656A1 (en) * 2021-02-08 2022-08-11 University Of British Columbia Anti-synucleinopathy peptide and methods to treat neurodegenerative diseases
TW202317147A (zh) 2021-07-08 2023-05-01 日商日本新藥股份有限公司 析出抑制劑
JPWO2023282345A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-07-08 2023-01-12
CN118201606A (zh) 2021-07-08 2024-06-14 日本新药株式会社 肾毒性减轻剂
CN113563429A (zh) * 2021-07-19 2021-10-29 天津大学 一种基于烷基化多肽的核酸递送系统及制备方法与应用
WO2023014909A1 (en) * 2021-08-04 2023-02-09 AJK Biopharmaceutical, LLC Amphiphilic peptides for nucleic acid and protein delivery
CN114106095B (zh) * 2021-11-11 2023-06-09 华南理工大学 基于聚集诱导发光原理的细胞自噬检测分子探针及其制备方法和应用
WO2023171804A1 (ja) 2022-03-10 2023-09-14 日本新薬株式会社 抗ウイルスアンチセンスオリゴマー
KR102717793B1 (ko) * 2022-05-26 2024-10-16 주식회사 바이오셀트란 신규한 미백 펩타이드 및 이를 함유하는 화장료 조성물
EP4547282A1 (en) 2022-06-30 2025-05-07 Life Technologies Corporation Lipid compositions for in vivo delivery
GB202211597D0 (en) 2022-08-09 2022-09-21 Nchain Licensing Ag Computer-implemented method and system
CN120615011A (zh) 2022-12-29 2025-09-09 生命科技股份有限公司 脂质组合物及用于递送到免疫细胞的方法
CN115947817B (zh) * 2023-02-22 2024-07-02 甘肃中肽生物科技有限公司 一种肿瘤相关多肽及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5316948A (en) 1992-09-04 1994-05-31 Life Technologies, Inc. N4 -methyl-2'-deoxycytidine 5'-triphosphate and its use in polymerase-catalyzed nucleic acid syntheses
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
EP0874910A4 (en) 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
DE69937964T2 (de) 1998-11-12 2009-01-02 Invitrogen Corp., Carlsbad Transportreagentien
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
PT1301213T (pt) * 2000-07-21 2017-04-19 Revance Therapeutics Inc Sistemas de transporte biológico de múltiplos componentes
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
GB0106315D0 (en) * 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
AU2004204456A1 (en) 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
JP4846588B2 (ja) 2003-05-22 2011-12-28 モレキュラー、トランスファー、インコーポレイテッド 核酸のトランスフェクションのための新規脂質
DK1653989T3 (da) * 2003-08-14 2009-11-23 Cellectis Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
CA2633063A1 (en) 2005-12-16 2007-06-21 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids intocells
US20100061932A1 (en) 2005-12-30 2010-03-11 Evonik Roehm Gmbh Peptides useful as cell-penetrating peptides
JP5313867B2 (ja) 2006-03-30 2013-10-09 ドライス ファーマシューティカルズ,インコーポレイティド カンプトテシン−細胞透過性ペプチド複合体及びそれを含む医薬組成物
CA2960570C (en) 2006-05-05 2018-05-08 Molecular Transfer, Inc. Lipids for transfection of eukaryotic cells
JP5403681B2 (ja) 2007-03-07 2014-01-29 独立行政法人国立国際医療研究センター 新規核内移行ペプチド
AU2009329893A1 (en) * 2008-12-23 2011-06-30 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US9006415B2 (en) * 2010-04-06 2015-04-14 Massachusetts Institute Of Technology Targeted delivery of nucleic acids
CA2800741C (en) * 2010-05-30 2018-07-24 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
NZ603732A (en) 2010-06-14 2015-02-27 Hoffmann La Roche Cell-penetrating peptides and uses therof
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
EP3470395A1 (en) 2010-11-15 2019-04-17 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same
CN102153629B (zh) * 2011-01-20 2013-07-24 华中科技大学 一种短肽及其应用
US8853145B2 (en) * 2011-11-14 2014-10-07 Carlos Witte-Hoffmann BLID; a novel protein domain for interaction with the Bcl-2 family of proteins
US20150266939A1 (en) 2012-03-15 2015-09-24 Permeon Biologics, Inc. Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use
EP3079723B1 (en) 2013-12-12 2020-05-27 Life Technologies Corporation Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
KR102476764B1 (ko) * 2015-12-23 2022-12-14 에스케이하이닉스 주식회사 소자분리구조 및 그 제조 방법
US9926825B2 (en) 2016-04-19 2018-03-27 GM Global Technology Operations LLC Method and apparatus for exhaust purification for an internal combustion engine

Also Published As

Publication number Publication date
EP3756690A3 (en) 2021-03-17
US20200392537A1 (en) 2020-12-17
SG11201604697TA (en) 2016-07-28
AU2014361806B2 (en) 2019-12-19
AU2020202002A1 (en) 2020-04-09
CN113105559A (zh) 2021-07-13
WO2015089487A1 (en) 2015-06-18
US12152248B2 (en) 2024-11-26
US9856496B2 (en) 2018-01-02
EP3079723A1 (en) 2016-10-19
KR102532559B1 (ko) 2023-05-16
US10760098B2 (en) 2020-09-01
US20150211021A1 (en) 2015-07-30
ES2808866T3 (es) 2021-03-02
AU2014361806A1 (en) 2016-07-28
SG10201811729PA (en) 2019-02-27
JP6985347B2 (ja) 2021-12-22
US20250109412A1 (en) 2025-04-03
EP3756690A2 (en) 2020-12-30
EP3079723B1 (en) 2020-05-27
US20180163231A1 (en) 2018-06-14
CN106456793A (zh) 2017-02-22
JP2020015747A (ja) 2020-01-30
US20250263751A1 (en) 2025-08-21
AU2020202002B2 (en) 2021-08-05
CA2933561A1 (en) 2015-06-18
KR20160103024A (ko) 2016-08-31
BR112016013516A8 (pt) 2020-05-19
CN106456793B (zh) 2021-04-30
JP6912887B2 (ja) 2021-08-04
JP2017500856A (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
AP2016009275A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR102016010778A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112015007533A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017733A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018502A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017739A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014019326A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018516A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017855A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018480A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014020341A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017765A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017669A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014021878A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018468A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017901A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014019204A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018207A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112015015948A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017722A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017653A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018578A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014018483A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017794A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112014017601A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]